Previous 10 | Next 10 |
The biotech industry continues to play a crucial role in developing solutions to treat critical ailments. In addition, the demand for biotech solutions is also high across other sectors such as food and agriculture. So, biotech stocks such as Leap Therapeutics (LPTX) and Corvus Pharmaceutical...
Gainers: Alzamend Neuro (NASDAQ:ALZN) +44%. Farmmi (NASDAQ:FAMI) +31%. Paltalk (NASDAQ:PALT) +29%. Onion Global (NYSE:OG) +27%. Progenity (NASDAQ:PROG) +23%. China Online Education (NYSE:COE) +17%. Meten Holding (NASDAQ:METX) +16%. Achilles Therapeutics (NASDAQ:ACHL) +13%. Crown Ele...
Gainers: Alzamend Neuro (NASDAQ:ALZN) +52%, Progenity (NASDAQ:PROG) +18%, OptimizeRx (NASDAQ:OPRX) +15%, Atea Pharmaceuticals (NASDAQ:AVIR) +14%, Perrigo (NYSE:PRGO) +11%. Losers: Corvus Pharmaceuticals (NASDAQ:CRVS) -15%, NuCana (NASDAQ:NCNA)...
Palm Beach, FL – September 28, 2021 – FinancialNewsMedia.com News Commentary More than 100 companies have rushed into vaccine development against COVID-19 as the U.S. government pushes for a vaccine rollout at “warp speed” — possibly by the end...
Gainers: FEIM +24.6%. LILM +6.5%. CNXC +6.0%. SCPS +5.5%. SGMS +4.3%. Losers: DOCU -6.1%. IMRX -5.0%. HIBB -1.7%. CRVS -1.6%. VG -1.5%. For further details see: FEIM, LILM, DOCU and IMRX among after hours movers
Corvus Pharmaceuticals (CRVS) has been making headway on several developments in the immuno-oncology therapies space, which sent its shares soaring to their 52-week high of $9.54 on September 21. However, the stock’s price has since declined on profit-taking. So, let’s find out ...
Shares rose by 135% on Friday alone, but as of Wednesday have still lost half their value since 2017. Additionally, current enterprise value is still around $260 million. ESMO data release for AstraZeneca's COAST study in lung cancer has potentially validated CD73 drug class, of which...
Shares of Corvus Pharmaceuticals (NASDAQ: CRVS) , a clinical-stage biotech, were down by 11.7% as of 2:43 p.m. EDT on Wednesday. Although the company announced the pre-print of results from its discontinued COVID-19 study evaluating the anti-CD73 antibody mupadolimab this morning, t...
Corvus stock has made spectacular gains across the past week, rising from a price of $2.3 to $8.5 - a 270% gain. Last week, AstraZeneca's Oleclumab - an anti-CD73 therapy - substantially improved the risk of death in combo with IMFINZI in NSCLC. Corvus' Mupadolimab is an anti-CD73...
Gainers: Marin Software MRIN +58%. Aethlon Medical (NASDAQ:AEMD) +33%. WiMi Hologram WIMI +32%. Onconova Therapeutics ONTX +25%. Dynavax DVAX +26%. Gaotu Techedu GOTU +18%. Candel (NASDAQ:CADL) +19%. Ramaco Resources (NASDAQ:METC) +16%. Celestica CLS +16%. Arqit ...
News, Short Squeeze, Breakout and More Instantly...
Corvus Pharmaceuticals Inc. Company Name:
CRVS Stock Symbol:
NASDAQ Market:
Corvus Pharmaceuticals Inc. Website:
Soquelitinib registrational Phase 3 clinical trial in PTCL advancing toward initial enrollment in Q3 2024 Fast track designation underscores unmet need for patients with relapsed or refractory PTCL, an indication with poor overall outcomes and no approved drugs based on randomized trial...
BURLINGAME, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 6, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update an...
Data demonstrated in vitro and in vivo ITK inhibition with soquelitinib induced switching of proinflammatory Th 17 cells into anti-inflammatory T reg cells Publication confirms and extends understanding of ITK inhibition mechanism of action and its potent...